Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A

Haemophilia

Volumn 15, Issue 4, 2009, Pages 881-887

  Miners, Alec ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cost; Economic evaluation; Haemophilia; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ARTICLE; BLEEDING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; ECONOMIC EVALUATION; EXPECTED VALUE OF PERFECT INFORMATION; HEMOPHILIA A; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILISTIC SENSITIVITY ANALYSIS; QUALITY ADJUSTED LIFE YEAR; REPEATED DRUG DOSE; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; FACTOR VIII; GREAT BRITAIN; HEMOPHILIA A; HUMANS; MALE; MARKOV CHAINS; NATIONAL HEALTH PROGRAMS; QUALITY OF LIFE; YOUNG ADULT;

EID: 67649848136     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02019.x     Document Type: Article

References (22)

1. Risebrough NA, Oh P, Blanchette V et al. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008; 14: 743-52.
2. Roosendaal G, Lafeber F. Prophylactic treatment for prevention of joint disease in hemophilia - cost versus benefit. N Engl J Med 2007; 357: 603-5.
3. Steen Carlsson K, Hojgard S, Lethagen S et al. Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden. Haemophilia 2004; 10: 527-41.
4. Steen Carlsson K, Höjgård S, Lindgren A et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 2004; 10: 515-26.
5. Miners AH, Sabin CA, Tolley KH et al. A cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics 2002; 20: 759-74.
6. Briggs AH, Goeree R, Blackhouse G et al. Probabilistic analysis of cost-effectiveness models: Choosing between strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22: 290-308.
7. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006.
8. Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. J Health Serv Res Policy 2008; 13(Suppl. 3): 23-30.
9. Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, England, 2005.
10. Gravelle S, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. J Health Econ 2001; 10: 587-600.
11. Claxton K, Ginnelly L, Sculpher MJ et al. A pilot study on the use of decision theory and value of information analysis as part of the National Health Service Health Technology Assessment Programme. Health Technol Assess 2004; 8: 1-118.
12. Nilsson IM. Experience with prophylaxis in Sweden. Semin Hematol 1993; 30(3 Suppl. 2): 16-9.
13. Nilsson IM, Berntorp E, Ljung R et al. Prophylactic treatment of severe hemophilia A and B can prevent joint disability. Semin Hematol 1994; 31(Suppl. 2): 5-9.
14. Nilsson IM, Berntorp E, Lofqvist T et.al. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
15. Miners AH, Sabin CA, Tolley KH et al. Assessing health-related quality-of-life in patients with severe haemophilia A and B. Psychol Health Med 1999; 4: 5-15.
16. Miners AH, Sabin CA, Tolley KH et al. Primary prophylaxis for individuals with severe haemophilia: How many hospital visits could treatment prevent? J Intern Med 2000; 247: 493-9.
17. Naraine VS, Risebrough NA, Oh P et al. Health-related quality-of-life treatments for severe haemophilia: Utility measurements using the Standard Gamble technique. Haemophilia 2002; 8: 112-20.
18. Keeling D, Tait C, Makris M. Guideline on the selection and use of theraputic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) Guideline. Approved by the British Committee for standards in Haematology. Haemophilia 2008; 14: 671-84.
19. Allain JP. Dose requirement for replacement therapy in hemophilia A. Thromb Haemost 1979; 42: 825-31.
20. Escobar MA. Products used to treat hemophilia: Dosing. In: Lee CA, Berntrop E, Hoots K, eds. Textbook of Hemophilia. Oxford: Blackwell Publishing Ltd, 2005: 153-7.
21. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. Available at: http://www.nice.org.uk/ niceMedia/pdf/TAP_Methods.pdf (last accessed on 1 July 2008).
22. Morris S, Devlin N, Parkin D. Economic Analysis in Health Care. Chichester: John Wiley and Sons, Ltd, 2007.